KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查 入排置信度 0.95

Updated results of the placebo-controlled, phase III JAKARTA trial of fedratinib in patients with intermediate-2 or high-risk myelofibrosis.

Animesh Pardanani, Ayalew Tefferi, Tamás Masszi, Elena Mishchenko, Mark Drummond, Eric Jourdan, Alessandro Vannucchi, Mindaugas Jurgutis, Vincent Ribrag, Alessandro Rambaldi, Liang Piu Koh, Shelonitda Rose, Jun Zhang, Claire Harrison

Br J Haematol 195(2) 244-248

PMID34331348
PMCIDPMC9292894
DOI10.1111/bjh.17727
发表日期2021-07-31
入排依据:The report describes a randomized, placebo-controlled Phase III trial of a drug (fedratinib) in oncology (myelofibrosis), but the primary efficacy endpoints are response rates (spleen volume response, symptom response), which are categorical, not time-to-event. There is no explicit mention of overall survival, progression-free survival, or any other time-to-event endpoint in the provided abstract.
摘要

摘要

Fedratinib, an oral Janus kinase-2 (JAK2) inhibitor, reduces splenomegaly and improves symptom burden in patients with myelofibrosis. Regulatory approval of fedratinib 400-mg daily was based on results of an updated analysis of the pivotal phase III, placebo-controlled JAKARTA trial in patients with JAK-inhibitor-naïve myelofibrosis. At week 24, spleen volume response rate was 47% and symptom response rate was 40% with fedratinib 400 mg, versus 1% and 9% respectively, with placebo. Common adverse events were diarrhoea, nausea, anaemia, and vomiting. No Wernicke encephalopathy occurred in patients receiving fedratinib 400 mg/day. These updated data support use of first-line fedratinib in patients with myelofibrosis.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。